# A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

> **NCT04594928** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 30 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** GLPG3667
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04594928
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2021-05-04
- **Final completion:** 2021-05-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594928, "A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04594928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*